Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACEPHEN vs ATACAND HCT
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
ACEPHEN (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, particularly COX-2, reducing prostaglandin synthesis. It has weak peripheral COX inhibition and minimal anti-inflammatory effect.
ATACAND HCT is a combination of candesartan, an angiotensin II receptor blocker (ARB), and hydrochlorothiazide, a thiazide diuretic. Candesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively antagonizing the AT1 receptor, leading to vasodilation and reduced blood pressure. Hydrochlorothiazide inhibits the sodium-chloride symporter in the distal convoluted tubule of the nephron, increasing sodium, chloride, and water excretion, thereby reducing plasma volume and blood pressure.
Mild to moderate pain,Fever
Treatment of hypertension, for patients not adequately controlled on monotherapy.
325-650 mg orally every 4-6 hours as needed; maximum 4 g/day.
One tablet orally once daily. Initial dose: 16 mg candesartan/12.5 mg hydrochlorothiazide. Titrate to maximum 32 mg candesartan/25 mg hydrochlorothiazide once daily.
Terminal elimination half-life: 1.0-1.5 hours in adults with normal renal function. Prolonged to 2-5 hours in hepatic impairment or elderly; requires dose adjustment in severe hepatic disease.
Candesartan: ~9 hours (terminal). Hydrochlorothiazide: 6-15 hours (terminal, mean ~10 hours).
Acetaminophen is primarily metabolized in the liver via glucuronidation (UGT1A1, UGT1A6, UGT1A9) and sulfation (SULT1A1, SULT1A3). A minor fraction is oxidized by cytochrome P450 enzymes (CYP2E1, CYP1A2, CYP3A4) to a reactive toxic metabolite (NAPQI), which is normally detoxified by conjugation with glutathione.
Candesartan is primarily metabolized by hepatic O-deethylation via CYP2C9 to an inactive metabolite. Hydrochlorothiazide is not significantly metabolized and is excreted unchanged by the kidneys.
Renal: 90-95% as unchanged drug; tubular secretion and glomerular filtration. Biliary/fecal: <5%.
Candesartan: ~33% renal, ~67% biliary/fecal. Hydrochlorothiazide: >95% renal.
Approximately 10-20% bound to serum albumin; extensive tissue binding.
Candesartan: >99% (primarily albumin). Hydrochlorothiazide: 40-70% (primarily albumin).
Apparent Vd: 0.5-0.7 L/kg (30-40 L in a 70 kg adult). Distributions into CSF and breast milk.
Candesartan: 0.13 L/kg (extensive tissue distribution). Hydrochlorothiazide: 0.83-2.5 L/kg (distributes into plasma and red blood cells).
Oral: 85-90% (first-pass metabolism minimal). Rectal: approximately 70-80% of oral bioavailability.
Candesartan: ~15% (absolute, prodrug conversion). Hydrochlorothiazide: ~70% (oral).
GFR 10-50 m L/min: 650 mg every 6 hours; GFR <10 m L/min: 650 mg every 8 hours.
Contraindicated if GFR <30 m L/min/1.73 m2. No adjustment for GFR 30-50 m L/min/1.73 m2. Use with caution and monitor renal function.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: maximum 2 g/day; Child-Pugh Class C: maximum 1 g/day.
Mild to moderate hepatic impairment (Child-Pugh A or B): No dose adjustment. Severe impairment (Child-Pugh C): Not recommended due to hydrochlorothiazide accumulation risk.
10-15 mg/kg/dose orally every 4-6 hours; maximum 75 mg/kg/day or 4 g/day, whichever is less.
Safety and efficacy not established in pediatric patients (<18 years).
Start at lowest effective dose (325 mg every 6 hours); avoid exceeding 3 g/day unless closely monitored.
No initial dose adjustment required. Use caution due to increased sensitivity to hypotension and electrolyte disturbances; monitor renal function and electrolytes.
Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed 4,000 milligrams per day, and often involve more than one acetaminophen-containing product.
None.
Risk of severe liver injury with doses >4000 mg/day; use caution with hepatic impairment, chronic alcoholism, malnutrition, or concomitant hepatotoxic drugs; avoid exceeding recommended dose; limit use to 10 days for pain or 3 days for fever unless directed by physician; serious skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis) have occurred.
Fetal toxicity: Use in pregnancy can cause oligohydramnios, fetal renal dysfunction, and skull ossification defects. Discontinue as soon as possible when pregnancy is detected.,Hypotension: Symptomatic hypotension may occur in volume-depleted patients. Correct volume depletion before initiation.,Impaired renal function: Monitor renal function due to risk of acute renal failure, especially in patients with renal artery stenosis.,Electrolyte imbalances: Hydrochlorothiazide can cause hypokalemia, hyponatremia, hypomagnesemia, and hypercalcemia; candesartan can cause hyperkalemia.,Metabolic effects: Thiazides may increase serum cholesterol, triglycerides, and uric acid levels; may cause hyperglycemia.,Acute angle-closure glaucoma: Hydrochlorothiazide can cause acute transient myopia and acute angle-closure glaucoma.,Systemic lupus erythematosus: Thiazides have been reported to cause exacerbation or activation of SLE.,Non-melanoma skin cancer: Thiazide diuretics may increase risk; monitor for skin lesions.
Hypersensitivity to acetaminophen or any component of the formulation; severe hepatic impairment or active liver disease.
Hypersensitivity to candesartan, hydrochlorothiazide, or any component of the formulation.,Anuria (hydrochlorothiazide component).,Pregnancy (second and third trimesters).,Severe renal impairment (Cr Cl <30 m L/min).,Concomitant use with aliskiren in patients with diabetes mellitus.
Alcohol: increased risk of hepatotoxicity. Avoid concurrent use. Food: no significant interaction, but taking with food may reduce minor gastrointestinal irritation.
Avoid salt substitutes containing potassium chloride unless approved by your doctor. Limit high-potassium foods (e.g., bananas, oranges, tomatoes) if hyperkalemia risk is present. Take hydrochlorothiazide with food or milk to reduce gastrointestinal upset. Grapefruit juice has no significant interaction with this combination.
Pregnancy Category C. First trimester: potential risk of neural tube defects and orofacial clefts (limited human data, animal studies show embryotoxicity). Second and third trimesters: NSAID exposure associated with oligohydramnios, premature ductus arteriosus constriction, and fetal renal impairment. Avoid in third trimester.
Pregnancy Category D. First trimester: potential fetotoxicity; second and third trimesters: ACE inhibitor exposure causes oligohydramnios, fetal renal dysfunction, skull ossification defects, and neonatal renal failure. Angiotensin receptor blocker (ARB) component: similar adverse effects. Thiazide diuretic: risk of fetal/neonatal jaundice, thrombocytopenia, and electrolyte disturbances. Use contraindicated in pregnancy.
Excreted into breast milk in low concentrations (M/P ratio approximately 0.10). Considered compatible with breastfeeding; however, use lowest effective dose for shortest duration given potential for neonatal adverse effects (e.g., thrombocytopenia, renal dysfunction).
Candesartan (ARB) and hydrochlorothiazide (HCTZ) are excreted in breast milk. M/P ratio not established for candesartan; HCTZ M/P ratio is approximately 0.6. HCTZ may suppress lactation. Use not recommended during breastfeeding due to potential adverse effects in the infant, including electrolyte imbalance, hypotension, and renal impairment.
No standard dose adjustments recommended; however, due to increased plasma volume and metabolism in pregnancy, higher doses may be required to achieve therapeutic effect. Avoid near term.
Dose adjustments not applicable; drug is contraindicated in pregnancy. If unintentionally exposed, discontinue as soon as pregnancy is detected. No dose adjustment recommendations for pregnancy due to lack of safe use data.
ACEPHEN (acetaminophen) is commonly used for mild to moderate pain and fever. Avoid exceeding 4 g/day in adults to prevent hepatotoxicity. In patients with hepatic impairment, reduce maximum daily dose to 2 g. Consider acetylcysteine for overdose. Onset of action is 15-30 minutes orally.
ATACAND HCT is a fixed-dose combination of candesartan (an angiotensin II receptor blocker) and hydrochlorothiazide (a thiazide diuretic). Monitor renal function and electrolytes, especially potassium and sodium, within 2 weeks of initiation and periodically thereafter. Avoid use in pregnancy; discontinue as soon as pregnancy is detected. May cause symptomatic hypotension, particularly in volume-depleted patients; correct volume depletion before starting. Can exacerbate gout due to thiazide-induced hyperuricemia. Not recommended for use with aliskiren in patients with diabetes or renal impairment (GFR <60 m L/min).
Do not exceed 4000 mg (4 grams) in 24 hours.,Avoid drinking alcohol while taking this medication.,Do not combine with other products containing acetaminophen.,Take with food if stomach upset occurs.,Seek immediate medical help if you experience symptoms of liver damage: yellowing of skin/eyes, dark urine, severe abdominal pain.
Do not take if you are pregnant, plan to become pregnant, or are breastfeeding.,Take exactly as prescribed; do not skip doses or double up.,Drink adequate fluids to prevent dehydration unless instructed otherwise by your doctor.,Avoid alcohol and NSAIDs (e.g., ibuprofen) as they may increase side effects.,Report symptoms like lightheadedness, excessive thirst, muscle cramps, or irregular heartbeat.,Monitor blood pressure regularly at home and keep a log.,This medication may increase sensitivity to sunlight; use sunscreen and protective clothing.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACEPHEN vs ATACAND HCT, answered by our medical review team.
ACEPHEN is a Non-Opioid Analgesic that works by ACEPHEN (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, particularly COX-2, reducing prostaglandin synthesis. It has weak peripheral COX inhibition and minimal anti-inflammatory effect.. ATACAND HCT is a Angiotensin II Receptor Blocker / Thiazide Diuretic that works by ATACAND HCT is a combination of candesartan, an angiotensin II receptor blocker (ARB), and hydrochlorothiazide, a thiazide diuretic. Candesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively antagonizing the AT1 receptor, leading to vasodilation and reduced blood pressure. Hydrochlorothiazide inhibits the sodium-chloride symporter in the distal convoluted tubule of the nephron, increasing sodium, chloride, and water excretion, thereby reducing plasma volume and blood pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACEPHEN and ATACAND HCT depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACEPHEN is: 325-650 mg orally every 4-6 hours as needed; maximum 4 g/day.. The standard adult dose of ATACAND HCT is: One tablet orally once daily. Initial dose: 16 mg candesartan/12.5 mg hydrochlorothiazide. Titrate to maximum 32 mg candesartan/25 mg hydrochlorothiazide once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACEPHEN and ATACAND HCT in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACEPHEN is classified as Category C. Pregnancy Category C. First trimester: potential risk of neural tube defects and orofacial clefts (limited human data, animal studies show embryotoxicity). Second and third trimest. ATACAND HCT is classified as Category C. Pregnancy Category D. First trimester: potential fetotoxicity; second and third trimesters: ACE inhibitor exposure causes oligohydramnios, fetal renal dysfunction, skull ossificati. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.